Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarrollo de nuevas terapias para tratar diversas patologías con altas necesidades médicas, se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio clínico de fase II/III en glioblastoma de...
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process....
The Spanish Bioindustry Association (AseBio), where Laminar Pharma is a member, has published its latest annual report on the state of the biotech sector in Spain, with updated data from 2020. ...
The Spanish government has announced the public grants corresponding to the State Program for research, development and innovation call — geared towards societal challenges and called "Collaboration Challenges of the year 2019". These are instruments to help meet the needs of the Spanish Science, Technology...
The Spanish government has announced the public grants corresponding to the State Program for research, development and innovation call — geared towards societal challenges and called "Collaboration Challenges of the year 2019". These are instruments to help meet the needs of the Spanish Science, Technology...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text] From the left, top: Adrian McNicholl, Gema Malet, Pablo V. Escribá, Ignacio Larrayoz, Paula Fernández y Roberto Beteta. Seated: Emilce Cano, Rafael Peláez, Catalina Rosselló, Raquel Rodríguez y Manuel Torres. November 20th, 2020 The Spanish government has announced...
Many drugs that are available in the market have something in common, regarding how they make effect: they directly target one or more proteins. And this is not a coincidence. Proteins perform a vast range of functions within the cells of all living organisms that...
A recent review article published by Laminar Pharma scientists in IJMS has awoken the interest of the scientific community....
Many drugs that are available in the market have something in common, regarding how they make effect: they directly target one or more proteins. And this is not a coincidence. Proteins perform a vast range of functions within the cells of all living organisms that...
Given the good track record of the stock market as an alternative source of financing, our company is taking its first steps to attract private investors and institutions, by joining the MAB stock market before the end of 2020. Nonpublic financing formulas such as Private...